

GEORGIA BOARD OF PHARMACY
Conference Call
2 Peachtree Street, NW, 6th Floor
Atlanta, GA 30303
March 31, 2017
10:00 a.m.

The following Board members were present:

Chris Jones, President
Bob Warnock, Vice-President
Vicki Arnold
Jim Bracewell
Mike Faulk

Staff present:

Tanja Battle, Executive Director
Rick Allen, Director, GDNA
Janet Wray, Senior Assistant Attorney General
Anil Foreman, Attorney
Brandi Howell, Business Support Analyst I

Visitors:

Karla Kiriako, Sanofi US

Open Session

President Jones established that a quorum was present and called the meeting to order at 10:05 a.m.

Bob Warnock made a motion to adopt emergency Rule 480-34-0.33-.12 Levocetirizine Dihydrochloride. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Rule 480-34-0.33-.12 Levocetirizine Dihydrochloride

(1) This rule was adopted to protect the health, safety, and welfare of the public. Levocetirizine dihydrochloride in 5 mg tablets or an oral solution of 2.5 mg per 5 mL (.05 mg per mL) is deleted from Official Code of Georgia Annotated (O.C.G.A.) §16-13-71(b)(516.75).

(2) This rule is based on the following findings of the Board:

(a) that levocetirizine dihydrochloride does not have a high potential for abuse;

(b) that the Board has considered the scientific evidence of its pharmacological effects; the state of current scientific knowledge regarding the drug; the history and current pattern of abuse; the scope, duration, and significance of abuse; the potential of the drug to produce psychic or physiological dependence liability; and

(c) that the drug, when in 5 mg tablets or an oral solution of 2.5 mg per 5 mL (.05 mg per mL), has been approved for non-prescription status by the Federal Food and Drug Administration.

The Board discussed Rule 480-34-0.32-.11 Naloxone. Mike Faulk made a motion to table this rule until the Board's meeting on April 12, 2017. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Correspondence from Mr. Tim Koch

The Board considered this correspondence requesting guidance concerning Naloxone. Mike Faulk made a motion to direct staff to respond to Mr. Koch by stating the pharmacist may use a telephone pad as long as he/she has the patient's information and the correct drug information on it when dispensing Naloxone pursuant to the Standing Order by Dr. Brenda Fitzgerald. Bob Warnock seconded and the Board voted unanimously in favor of the motion.

There being no further business to discuss, the meeting was adjourned at 10:15 a.m.

The next meeting of the Georgia Board of Pharmacy is scheduled for Wednesday, April 12, 2017 at 9:00 a.m. at Georgia Baptist College of Nursing-Mercer University, 3001 Mercer University Drive, Room 137, Atlanta, GA 30341.

Minutes recorded by Brandi Howell, Business Support Analyst I
Minutes edited by Tanja D. Battle, Executive Director